

Mr. Iñigo de la Lastra

Head of Secondary Markets

CNMV

Edison 4

28006 Madrid

Valencia (Spain), October 24, 2014

RELEVANT FACT

Dear Sir,

In accordance with Article 82 of Law 24/1988, 28th July, relative to the regulation of the stock market and related provisions, NATRACEUTICAL SA hereby informs that the respective Shareholders General Meetings of Natraceutical SA and Laboratorio Reig Jofre SA approved today the merger by absorption of Laboratory Reig Jofre SA by Natraceutical SA.

With regard to the Extraordinary Shareholders General Meeting of Natraceutical SA, it has been held upon the first call on October 24, 2014 with the agenda established and with 47,08% of present shareholders and 5,92% represented, totally representing 53,00% of the share capital..

All resolutions were adopted by majority of the present or represented shareholders in the following sense:

- I. It was approved as the merger balance of Natraceutical SA, the balance dated December 31, 2013 approved by the Ordinary General Shareholders Meeting on June 30, 2014.
- II. It was approved the merger project through the absorption of Laboratorio Reig Jofre SA by Natraceutical SA, approved by the Boards of both companies at the meetings held on June 26th, 2014.
- III. It was approved the merger through absorption of Laboratorio Reig Jofre SA, by Natraceutical SA, subject to Laboratorio Reig Jofre, SA's sole shareholder, the company Reig Jofre Investments SL, obtaining the exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.

Head Office:

Av. Alcalde Barnils 64-68, A, 1st floor, 3
08174 St. Cugat del Vallès, Barcelona
Spain
Tel. [+34] 93 584 81 85
Fax. [+34] 93 584 81 90

natraceutical

- IV. It was approved the capital increase as described in the merger project and the corresponding modification of Article 5 of the corporate bylaws relative to the share capital and shares, subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining the exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- V. It was approved the application for admission to trading of the new shares on the Bilbao, Madrid, Barcelona and Valencia Stock Exchanges via the interconnection trading system (continuous market), subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining the exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- VI. It was approved the amendment of Article 1 of the corporate bylaws relative to the name and legal status, subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- VII. It was approved the amendment of Article 2 of the corporate bylaws relative to the corporate purpose, subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- VIII. It was approved the amendment of Article 4 of the corporate bylaws relative to the registered offices, subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining the exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- IX. It was approved the revised bylaws, subject to Laboratorio Reig Jofre SA's sole shareholder, the company Reig Jofre Investments SL, obtaining the exemption from the Spanish Stock Exchange Commission (CNMV) from the obligation to formulate a takeover bid.
- X. It was approved to request the admission of the merger to the special tax regime under Chapter VIII of Title VII and the Second Additional Provision of the revised Company Tax Law.
- XI. It was approved the following resolution subject to the registration in the Mercantile Register of the merger between Laboratorio Reig Jofre SA and Natraceutical SA, in the following sense:
 1. It was accepted the resignation of the current members of the board of directors with effect from the date of the registration of the merger.

natraceutical

2. It was agreed to set in nine the number of board members.
 3. It was reelected Natra SA as a member of the board for the statutory period of five (5) years, with effect from the date of the registration of the merger and the following board members were also appointed:
 - (i) Antón Costas Comesaña, as independent director;
 - (ii) Maria Luisa Francoli Plaza, as independent director;
 - (iii) Ramiro Martínez-Pardo del Valle, as independent director;
 - (iv) Emilio Moraleda Martinez, as an independent director;
 - (v) Ramon Gomis i Barbarà, as independent director;
 - (vi) Natra SA, as proprietary director;
 - (vii) Reig Jofre Investments SL, as proprietary director;
 - (viii) Ignasi Biosca Reig, as proprietary director proposed by Reig Jofre Investments SL; and
 - (ix) Alejandro García Reig, as proprietary director proposed by Reig Jofre Investments SL.
- XII. It was approved the removal, for just cause, of the appointment of the auditors PriceWaterhouseCoopers SL as auditor of the individual and consolidated annual accounts of the company, as approved at the shareholders general meeting of June 30, 2014 to audit the annual accounts of the company closed at 31 December 2014 and it was appointed as the new auditor of the company KPMG Auditors SL to audit the annual individual and consolidated accounts the following three years, ie the years ended December 31, 2014, December 31, 2015 and December 31, 2016.
- XIII. The chairman and secretary of the board of directors were granted powers for the development, documentation and implementation of the resolutions adopted by the Extraordinary Shareholders General Meeting.

Yours faithfully,

M^a José Busutil Santos
Secretary of the Board of Directors
NATRACEUTICAL, S.A.